文献速递角膜与眼表疾病

角膜交联

Corneal cross-linking.
PubMed 文献 · Prog Retin Eye Res · 2024-12-15

本文综述角膜交联(CXL)从经典德累斯顿方案(核黄素饱和联合30分钟3 mW/cm²紫外线A照射)到加速方案、巩膜透镜及扩展适应证的进展,涵盖圆锥角膜等角膜扩张症、感染性角膜炎(PACK-CXL)、角膜新生血管、无菌性融解、炎症性干眼,以及与屈光手术联合应用。

要点

  • 德累斯顿方案需去上皮且最小角膜厚度400 μm以保护内皮。
  • 加速CXL方案缩短并简化操作时间,同时维持有效性和安全性。
  • PACK-CXL利用活性氧直接杀灭病原体,交联通过位阻增强角膜抗蛋白酶消化。

核心结论

  • CXL已从单纯改善角膜扩张的生物力学,扩展为多层次调节角膜生理和生化的技术,适应证包括其他角膜扩张、角膜新生血管、无菌性融解、炎症性干眼及感染性角膜炎(PACK-CXL)。

研究设计与样本

  • 本文为综述,检索范围原文未报告。

主要发现

  • 德累斯顿方案包括核黄素饱和角膜基质后以3 mW/cm²强度紫外线A照射30分钟,产生活性氧交联基质分子以僵硬角膜。
  • 核黄素分子因体积大难以通过角膜上皮紧密连接,故德累斯顿方案需上皮刮除。
  • 德累斯顿方案要求最小角膜厚度400 μm以保护内皮免受紫外线损伤。
  • 加速CXL方案利用对氧和光化学反应的认识缩短并简化操作时间,同时维持有效性和安全性。
  • PACK-CXL中活性氧直接杀灭病原体,交联通过位阻增强角膜抵抗病原体蛋白酶消化。

关键数值与推荐

  • 德累斯顿方案:核黄素饱和后30分钟3 mW/cm²紫外线A照射。
  • 德累斯顿方案最小角膜厚度400 μm。
  • PACK-CXL采用更高紫外线能量和其他色团/光组合,具体为玫瑰红和绿光。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

First introduced over 20 years ago as a treatment for progressive keratoconus, the original "Dresden" corneal cross-linking (CXL) protocol involved riboflavin saturation of the stroma, followed by 30 min of 3 mW/cm2-intensity ultraviolet-A (UV-A) irradiation. This procedure generates reactive oxygen species (ROS) that cross-link stromal molecules, thereby stiffening the cornea and counteracting the ectasia-induced weakening. Due to their large size, riboflavin molecules cannot readily pass through the corneal epithelial cell tight junctions; thus, epithelial debridement was performed. Moreover, the Dresden protocol necessitates a minimal corneal thickness of 400 μm to protect the endothelium from UV-induced damage. While the Dresden protocol is highly effective at enhancing corneal biomechanical strength, there was a strong desire for CXL procedures that would deliver Dresden-like strengthening in a shorter time, in corneas thinner than 400 μm, and without requiring epithelial debridement. This review explores the advancements and scientific discoveries that have enabled such improvements. Accelerated CXL protocols, utilizing our increased knowledge about the role of oxygen and photochemical reactions in the cornea have shortened and simplified the procedure duration while maintaining efficacy and safety, improving clinical workflow and patient compliance. CXL is not confined to improving biomechanics in corneal ectasia, but rather represents a technique that modulates corneal physiology and biochemistry on multiple levels. Accordingly, CXL indications have expanded to include treating other corneal ectasias, corneal neovascularization, corneal sterile melting, inflammatory dry eye and importantly, infectious keratitis in a procedure termed photoactivated chromophore for keratitis-CXL (PACK-CXL). In PACK-CXL, ROS have a direct pathogen-killing effect, and cross-linking enhances the cornea's resistance to pathogen-produced protease digestion through steric hindrance. The distinct requirements of PACK-CXL compared to ectasia treatment have led to the development of different CXL protocols, including higher UV fluences and other chromophore/light combinations, specifically rose bengal and green light. Additionally, combining CXL with vision-enhancing procedures like individualized wavefront- or topographically-guided excimer ablation can regularize a biomechanically stable cornea, improve visual acuity, and potentially eliminate the need for corneal transplantation, leading to long-term improvements in quality of life.

来源:Prog Retin Eye Res,查看原文。版权归原作者所有。

引用

  1. Hafezi F, Kling S, Hafezi NL, et al. Corneal cross-linking. Prog Retin Eye Res. 2024. PMID: 39681212. doi:10.1016/j.preteyeres.2024.101322

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。